Nutex Health (NUTX) Set to Post Earnings on Thursday

Nutex Health (NASDAQ:NUTX) is expected to post its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to post earnings of $5.54 per share and revenue of $214.82 million for the quarter. Individuals may review the information on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 6, 2026 at 10:30 AM ET.

Nutex Health (NASDAQ:NUTX) last announced its quarterly earnings data on Thursday, August 6th. The company reported $9.38 earnings per share for the quarter, beating the consensus estimate of $4.95 by $4.43. Nutex Health had a net margin of 21.25% and a return on equity of 39.74%. The business had revenue of $210.75 million for the quarter, compared to analyst estimates of $215.03 million. On average, analysts expect Nutex Health to post $27.58 EPS for the current fiscal year and $28.70 EPS for the next fiscal year.

Nutex Health Price Performance

NUTX opened at $212.63 on Thursday. The company has a fifty day moving average price of $202.62 and a two-hundred day moving average price of $150.48. The company has a debt-to-equity ratio of 0.59, a quick ratio of 4.96 and a current ratio of 5.00. Nutex Health has a 52 week low of $83.99 and a 52 week high of $226.16. The firm has a market capitalization of $1.46 billion, a PE ratio of 8.35 and a beta of 0.55.

Insider Transactions at Nutex Health

In other Nutex Health news, Director Scott Saunders sold 203 shares of the company’s stock in a transaction that occurred on Friday, September 18th. The shares were sold at an average price of $214.25, for a total value of $43,492.75. Following the completion of the sale, the director owned 400 shares of the company’s stock, valued at approximately $85,700. This represents a 33.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 44.68% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on NUTX shares. Weiss Ratings raised Nutex Health from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Tuesday, October 6th. Lake Street Capital reaffirmed a “buy” rating and set a $310.00 price objective (up from $235.00) on shares of Nutex Health in a research note on Tuesday, August 11th. Wall Street Zen raised Nutex Health from a “hold” rating to a “buy” rating in a research note on Saturday, October 3rd. Zacks Research downgraded Nutex Health from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 6th. Finally, LADENBURG THALM/SH SH assumed coverage on Nutex Health in a research note on Monday. They issued a “buy” rating and a $336.00 target price on the stock. Four investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $323.67.

About Nutex Health

Nutex Health, Inc (NASDAQ:NUTX) is a physician-led healthcare services company that operates an integrated network of hospitals, medical facilities and physician practices in the United States. The company focuses on providing convenient, community-based care through its micro-hospitals and other healthcare locations.

Its hospital operations generally include emergency services, inpatient care, diagnostic testing and outpatient treatment. Nutex also operates physician networks and supports primary care and specialty providers.